Market Overview

Facebook Returns Fire In BlackBerry Legal Battle With Patent Infringement Accusations

Share:
Facebook Returns Fire In BlackBerry Legal Battle With Patent Infringement Accusations
Related BB
The Week Ahead: Pepsi And Costco Earnings, Upwork IPO
46 Biggest Movers From Friday
Related FB
FANG Weakness Drags New Communication Services ETFs
Midterms And The Stock Market: Potential Winners, Losers From The Coming Election
Brunch, Craft Beer & Investing: Embracing Volatility & Managing Risk (Seeking Alpha)

A legal battle between social media giant Facebook, Inc. (NASDAQ: FB) and BlackBerry Ltd (NYSE: BB) expanded Tuesday after the social media giant filed suit against the Canadadian software company for patent infringement.

What Happened

BlackBerry accused Facebook in a lawsuit in March of infringing on its mobile messaging patents. On Wednesday, Facebook returned fire with a 118-page complaint in which it accuses BlackBerry of infringing on six of its patents.

Facebook said BlackBerry is actively infringing on some of its patented process technologies related to voice messaging; how a mobile device shows graphics to users; and the analysis of GPS data, The Verge reported. Facebook is demanding unspecific damages.

Why It's Important

BlackBerry shares were trading lower by 4.6 percent at $10.15 at the time of publication Wednesday. 

Investors are likely showing signs of concerns as Facebook fights back. A Bloomberg report said BlackBerry hadn't responded to requests for comment that were sent after hours. 

What's Next

Facebook's lawsuit was filed in U.S. District Court in San Francisco. 

Related Links:

BlackBerry Has Become A Story Of Continued Progress And Diminishing Headwinds

Facebook 'Hit Reset' On Expectations: Wall Street Responds To The Lackluster Quarter

Posted-In: Bloomberg Messaging patentNews Legal Top Stories Tech Media Best of Benzinga

 

Related Articles (BB + FB)

View Comments and Join the Discussion!

This Day In Market History: Japanese Investor Buys Pebble Beach Golf Resort In Infamous Real Estate Deal

Histogenics Slips Below $1 Threshold After Knee Cartilage Candidate Fails Late-Stage Study